Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Volume 58 , Issue 20
Showing 1-28 articles out of 28 articles from the selected issue
ORIGINAL ARTICLES
  • Miwa Kawanaka, Tomohiro Tanikawa, Tomoari Kamada, Katusinori Ishii, No ...
    2019 Volume 58 Issue 20 Pages 2907-2913
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: July 10, 2019
    JOURNALS OPEN ACCESS

    Objective To evaluate the prevalence of autoimmune gastritis in patients with histologically proven nonalcoholic steatohepatitis (NASH).

    Methods A total of 33 patients with NASH and 143 patients with chronic liver disease (66, 24, 22, 10, 1, and 21 patients with hepatitis C, hepatitis B, autoimmune hepatitis/primary biliary cholangitis, non-B/non-C hepatitis, fatty liver, and alcoholic disease, respectively) who underwent upper gastrointestinal endoscopy between January 2013 and August 2016 were retrospectively assessed to determine the prevalence of autoimmune gastritis. The clinical characteristics of these patients with NASH and autoimmune gastritis were examined, and the clinical characteristic and biomarkers were compared between patients with NASH with and without autoimmune gastritis.

    Results Six of the 33 patients with NASH (19.4%) were diagnosed with autoimmune gastritis. The prevalence of autoimmune gastritis was higher in patients with NASH than in those with other chronic liver diseases [4/143 (2.8%), p=0.002]. All six patients with NASH and autoimmune gastritis exhibited high serum gastrin levels; five of the patients were positive for anti-parietal cell antibodies, and one was negative for anti-parietal cell antibodies but positive for intrinsic factor antibody. Furthermore, 1 patient presented with iron-deficiency anemia (hemoglobin <11 g/dL), but none developed pernicious anemia. Endocrine cell micronests were found in four patients. Patients with NASH and autoimmune gastritis tended to be older with lower ferritin levels than the other patients.

    Conclusion The prevalence of NASH with concomitant autoimmune gastritis was high, highlighting the need for upper endoscopy for the diagnosis of autoimmune gastritis and gastric malignancies.

    Download PDF (1339K)
  • Shinjiro Inomata, Akira Anan, Eri Yamauchi, Ryo Yamauchi, Hideo Kunimo ...
    2019 Volume 58 Issue 20 Pages 2915-2922
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Objective Hepcidin is a master iron regulator hormone produced by the liver, but precise mechanism underlying its involvement in iron overload in hepatitis C virus (HCV) infection remains unclear. We investigated the serum hepcidin levels against iron overload before and after HCV eradication.

    Methods We prospectively investigated the iron metabolism characteristics in 24 patients with HCV genotype 1b infection before and after treatment. We also assessed the serum erythroferrone (ERFE) levels to investigate its association with iron metabolism changes. Patients were treated with Ledipasvir 90 mg and Sofosbuvir 400 mg once daily for 12 weeks and observed for 12 more weeks in order to evaluate their sustained virological response.

    Results Serum hepcidin levels at baseline were in the normal range, although serum ferritin levels were increased. After HCV eradication, both serum ferritin and hepcidin levels were significantly decreased at 24 weeks from baseline (p<0.001, p=0.006, respectively). However, the serum hepcidin-to-ferritin ratios were significantly increased (p<0.001). In addition, the serum ERFE levels were significantly decreased (p<0.001). Increases in the serum hepcidin-to-ferritin ratios were correlated with decreases in the serum ERFE levels (ρ=−0.422, p=0.039).

    Conclusion Serum hepcidin levels were relatively low against ferritin levels in HCV infection. However, after HCV eradication, the serum hepcidin-to-ferritin ratios were increased. These results indicate the improvement of inadequate hepcidin secretion against iron overload after HCV eradication. Downregulation of ERFE may have affected the improvement of iron metabolism.

    Download PDF (465K)
  • Ken Kageyama, Akira Yamamoto, Atsushi Jogo, Takehito Nota, Kazuki Mura ...
    2019 Volume 58 Issue 20 Pages 2923-2929
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Objective Therapeutic predictors derived from the venous pressure before therapy have not been identified for Budd-Chiari syndrome (BCS). The aim of this study was to determine whether or not measuring the distal pressure or pressure gradient was useful for predicting treatment efficacy in BCS.

    Methods We retrospectively analyzed seven consecutive patients diagnosed with symptomatic BCS at our hospital between 2008 and 2017. Distal and proximal venous pressures at occlusion sites of BCS were measured before treatment in all cases. The pressure gradient was defined as the difference between distal and proximal venous pressures. A receiver operating characteristics (ROC) analysis was performed for venous pressures.

    Results Percutaneous old balloon angioplasty (POBA) was performed in seven cases, with technical success achieved in all cases (100%). No complications were encountered. The median primary patency was 574 (interquartile range, 439.5-1,056.5) days. The 1-year primary patency rate was 71.73%. Six cases (85.7%) showed resolution of symptoms, representing clinical success. The ROC analysis revealed a high distal pressure (area under the ROC curve = 0.83, cut-off=12 mmHg) as a predictor of treatment efficacy of POBA for symptomatic BCS. In addition, the pressure gradient was considered significant from a clinical perspective, because the 6 successful cases with resolution of symptoms showed a large pressure gradient (range, 8-21 mmHg) before treatment, whereas the failed case showed a relatively small pressure gradient (7 mmHg).

    Conclusion High distal pressure and a large pressure gradient might predict the treatment efficacy of balloon angioplasty for symptomatic BCS.

    Download PDF (863K)
  • Masato Matsushita, Akihiro Shirakabe, Nobuaki Kobayashi, Hirotake Okaz ...
    2019 Volume 58 Issue 20 Pages 2931-2941
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Objective The aim of present study was to elucidate the gender differences in social determinants among patients with acute heart failure (AHF).

    Methods A total of 1,048 AHF patients were enrolled, and the 508 AHF patients who were ≥75 years old and the 540 patients who were <75 years old were evaluated as the elderly and non-elderly cohorts, respectively. Participants who met one of the three marital status-, offspring-, and living status-related criteria were considered socially vulnerable, and subjects were thus classified into socially vulnerable and non-socially vulnerable groups by gender in both the non-elderly and elderly cohorts. Social vulnerability was significantly more common in the elderly cohort (n=246, 48.4%) than in the non-elderly cohort (n=197, 36.5%) and significantly more common in the elderly women (n=157, 69.4%) than in the elderly men (n=89, 31.5%). Kaplan-Meier curves showed that the survival rate of the socially vulnerable group was significantly poorer than that of the non-socially vulnerable group in the elderly male cohort (p=0.010). Social vulnerability was an independent predictor of the 1,000-day mortality in the elderly male cohort (hazard ratio: 1.942, 95% confidence interval: 1.102-3.422) but not in the elderly female cohort according to a multivariate analysis.

    Conclusion Social vulnerability was shown to be more common in elderly female AHF patients than in elderly men, although it was associated with a poor prognosis in elderly men. Reinforcing the social structure of elderly male AHF patients might help improve their prognosis.

    Download PDF (1675K)
  • Takashi Murata, Atsuhito Tone, Ryuji Kouyama, Kenji Kamiuchi, Kohshi N ...
    2019 Volume 58 Issue 20 Pages 2943-2948
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Objective We compared the pain accompanying the injection of high-concentration (300 units/mL) insulin glargine (U300G) with that accompanying the injection of conventional (100 units/mL) insulin glargine (U100G).

    Methods U100G was switched to U300G at basically the same dosage. Visual analog scales were used to assess the quality of life (QOL). The primary outcome was the change in the pain accompanying injections in those using ≥30 units of U100G compared with those using <30 units at baseline. Standardized mean differences (Cohen's d) were used to measure the effect size.

    Patients Adult patients with type 2 diabetes mellitus using U100G.

    Results One hundred and eight patients were recruited. The numbers of patients who used U100G at ≥30 units, 20 to <30 units, 10 to <20 units, and <10 units were 13, 14, 34, and 47, respectively. The improvement in the pain score was not significant for ≥30 units compared with <30 units (-50.3±24.0 vs. -40.4±28.5, p=0.25, d=0.38), but a significant difference was observed for ≥20 units compared with <20 units (-50.8±22.7 vs. -38.4±29.1, p=0.03, d=0.48), as well as for ≥10 units compared with <10 units (-48.1±25.0 vs. -33.0±29.7, p<0.01, d=0.56). When all patients were analyzed together, significant improvements in the pain score (-41.5±28.0, p<0.01), ease of use score (-37.5±32.2, p<0.01), force needed to inject score (-46.5±28.6, p<0.01), and preference for U300G compared with U100G score (-45.8±33.1, p<0.01) were observed.

    Conclusion There is possibility that switching from U100G to U300G might be associated with better QOL for patients who require insulin glargine injections. To prove this hypothesis, a randomized controlled trial (preferably double-blinded) will be required in the future.

    Download PDF (386K)
CASE REPORTS
  • Shumpei Yamamoto, Masaya Iwamuro, Muneaki Miyake, Naoyuki Nishimura, M ...
    2019 Volume 58 Issue 20 Pages 2949-2955
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: July 10, 2019
    JOURNALS OPEN ACCESS

    A 49-year-old man with diabetes taking clopidogrel and celecoxib underwent interbody fusion surgery for spinal spondylolysis. Ten days after the surgery, he vomited a large amount of fresh blood. A blood examination revealed hemodynamic failure. Esophagogastroduodenoscopy showed an adherent blood clot and multiple superficial ulcers in the esophagus. Endoscopic hemostasis was successfully achieved. Biopsy specimens from the esophageal ulcer showed positive immunohistochemical staining results for anti-CMV antibodies. The esophageal ulcer improved after the oral administration of ganciclovir. This case emphasizes that CMV esophagitis with bleeding can occur in a diabetic patient with a poor nutritional status due to relative immune dysfunction.

    Download PDF (1172K)
  • Makoto Ueno, Fumio Nagashima, Hideki Ueno, Masafumi Ikeda, Shinichi Oh ...
    2019 Volume 58 Issue 20 Pages 2957-2962
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Gemcitabine plus nab-paclitaxel is the current standard chemotherapy for patients with metastatic pancreatic cancer. We conducted a phase I/II study in Japan, in which high response rates and manageable toxicity were observed. In this study, two patients were reported as experiencing pancreatitis due to chemotherapy. In general, pancreatitis is sometimes observed when the tumor involves the pancreatic duct, and the onset is observed before the diagnosis or at the initial stage. The onset of pancreatitis in these cases was unique and observed after the start of chemotherapy. Pancreatitis may be induced by the alleviation of stenosis of the pancreatic duct associated with tumor shrinkage.

    Download PDF (3893K)
  • Naoto Sato, Shunji Watanabe, Kouichi Miura, Rie Goka, Naoki Morimoto, ...
    2019 Volume 58 Issue 20 Pages 2963-2968
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 65-year-old man presented with acute liver failure and grade IV coma caused by hepatitis B virus (HBV) infection in 2017. The patient died on day 12 from the disease onset. The HBV isolated from the patient was genotype/subgenotype B/B1 and had multiple genomic mutations. The patient's wife was hepatitis B surface antigen (HBsAg)-positive when she delivered her first daughter in 1979. The HBV isolates of the patient and the wife shared 100% similarity over the entire genome. Because the patient's HBsAg value had been negative one year earlier, we considered the source of HBV transmission to be his wife.

    Download PDF (1792K)
  • Takeshi Hatanaka, Atsushi Naganuma, Yumeo Tateyama, Fukiko Yoshinari, ...
    2019 Volume 58 Issue 20 Pages 2969-2975
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 72-year-old Japanese man was referred to our hospital with yellow discoloration of the sclera and liver dysfunction. He was diagnosed with acute hepatitis C virus (HCV) infection on the basis of HCV-RNA positivity and anti-HCV seroconversion. A transjugular liver biopsy confirmed submassive hepatic necrosis. Five days after admission, no flapping tremor was observed, and the prothrombin time-international normalized ratio (PT-INR) and total bilirubin level showed increases of 1.70 and 17.8 mg/dL, respectively. The Model for End-Stage Liver Disease score was determined to be 25, and the risk of acute liver failure (ALF) was estimated to be 48% according to the Japan Hepatic Encephalopathy Prediction Model. Considering that rapid HCV clearance and temporary suppression of the immune response would prevent ALF, we prescribed oral ledipasvir (LDV) 90 mg and sofosbuvir (SOF) 400 mg for 12 weeks and intravenously injected methylprednisolone 1 g for 3 days. His PT-INR promptly improved, although the total bilirubin level increased to 30.3 mg/dL. Plasma bilirubin absorption was performed three times, and the total bilirubin level gradually decreased. HCV-RNA was still detectable at six weeks after the start of LDV/SOF therapy and finally undetectable at eight weeks. There were no adverse events associated with LDV/SOF. The patient was discharged 73 days after admission. A sustained virological response was achieved at 12 and 24 weeks after treatment. The findings from this case suggest that LDV/SOF therapy can be a promising option for acute HCV monoinfection associated with a high risk of ALF.

    Download PDF (503K)
  • Sonoko Kamijo, Satoru Hasuike, Kenichi Nakamura, Yuuka Takaishi, Yuri ...
    2019 Volume 58 Issue 20 Pages 2977-2982
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 72-year-old man was admitted to a general hospital with progressive liver dysfunction, hypokalemia, hyperglycemia, and nodules in the lung and liver and then transferred to our institution on the seventh hospital day. Plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and neuron-specific enolase concentrations were extremely high. He developed acute liver failure, his consciousness and general condition deteriorated rapidly, and he died on Day 11. At the postmortem examination, he was found to have extensive metastases from small-cell lung cancer, including advanced hepatic metastases. This is the first reported case of acute liver failure caused by metastases derived from an ACTH-producing pulmonary small-cell carcinoma.

    Download PDF (966K)
  • Mari Tanaka, Sho Miki, Hirona Saita, Hiroki Shimada, Seira Nishikawa, ...
    2019 Volume 58 Issue 20 Pages 2983-2988
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    MYH9-related disease is a rare genetic disorder characterized by macrothrombocytopenia, with frequent proteinuric nephropathy, hearing loss, and cataract. Although proteinuric nephropathy usually progresses to renal failure, there is no established treatment for the nephropathy. We herein describe the case of a 19-year-old man carrying an E1841K MYH9 mutation, who developed persistent proteinuria. The patient was diagnosed with early-stage MYH9-related nephropathy based on the histological examination of a kidney biopsy specimen. The patient was treated with enalapril, which significantly reduced the proteinuria with no decline in his renal function. The early administration of renin-angiotensin system blockade therapy may have beneficial effects on MYH9-related nephropathy in patients with E1841K mutations. We also briefly summarize previously published cases of MYH9-related nephropathy treated with renin-angiotensin system (RAS) blockade therapy.

    Download PDF (1089K)
  • Takashi Iijima, Noriko Hayami, Kenmei Takaichi, Naoya Morisada, Kandai ...
    2019 Volume 58 Issue 20 Pages 2989-2992
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Orofaciodigital syndrome 1 (OFD-1) is a rare, X-linked, dominantly inherited disorder caused by an OFD1 mutation that can cause polycystic kidneys. A 37-year-old woman on hemodialysis therapy was admitted to our hospital for trans-catheter arterial embolization therapy for enlarged polycystic kidneys. Lobulated tongue and brachydactyly were noticed, prompting an OFD1 sequencing analysis. Sequencing revealed a causal four-base-pair deletion in exon 13, both in the patient and in her mother, whose renal function had been retained. The peripheral leukocyte X chromosome inactivation pattern was skewed in the patient but not in her mother, suggesting some role in their phenotypic difference.

    Download PDF (811K)
  • Yuji Kato, Ayako Ishikawa, Satoshi Aoki, Hiroyuki Sato, Yoshie Ojima, ...
    2019 Volume 58 Issue 20 Pages 2993-3000
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Fabry disease (FD) is a rare X-linked hereditary disorder (Xq22) caused by a deficiency in alpha-galactosidase activity. A 34-year-old man was referred to our hospital because of renal dysfunction. He had previously undergone pacemaker implantation at 24 years of age. Investigations revealed undetectable alpha-galactosidase A activity levels. Renal biopsy results indicated vacuolization of podocytes. A genetic analysis revealed that the patient carried the W340X mutation. Enzyme replacement therapy with agalsidase beta was started. This case is novel because most cases of FD nephropathy precede cardiac disease. In our patient, the cardiac event was the initial event, and renal impairment followed.

    Download PDF (1697K)
  • Chieko Kawakita, Masaru Kinomura, Nozomu Otaka, Masashi Kitagawa, Hito ...
    2019 Volume 58 Issue 20 Pages 3001-3007
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 57-year-old man was diagnosed with IgA nephropathy. Hematuria and proteinuria were improved by tonsillectomy plus methylprednisolone pulse therapy. Lymphadenopathy, hypocomplementemia and pancytopenia were observed six years later, and urinalysis abnormalities recurred. A biopsy revealed mesangial proliferative glomerulonephritis with C3-dominant deposition. Human immunodeficiency virus (HIV) antibody demonstrated positive conversion. He was diagnosed with HIV-associated immune complex kidney disease (HIVICK). The hematuria, proteinuria and hypocomplementemia were improved by reducing the HIV viral load through antiretroviral therapy. When C3-dominant deposition is observed on a renal biopsy, HIVICK must be differentiated.

    Download PDF (1172K)
  • Kohichi Takada, Kazuyuki Murase, Hajime Nakamura, Naotaka Hayasaka, Yo ...
    2019 Volume 58 Issue 20 Pages 3009-3012
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Pneumothorax has been reported as a pazopanib-associated adverse event in patients with lung metastases of soft tissue sarcoma (STS). However, pneumothorax triggered by eribulin treatment has never been reported. We herein report two cases of spontaneous pneumothorax in patients with STS treated with eribulin. Both patients experienced pneumothorax accompanied by sudden dyspnea on day 9 or 10 of eribulin treatment. These two cases suggest that spontaneous pneumothorax may occur as an adverse event of eribulin treatment in such patients. We should therefore be alert for the potential development of pneumothorax during eribulin treatment of patients with STS and lung metastases.

    Download PDF (3033K)
  • Masahiro Nemoto, Kenjin Nishioka, Jun Fukuoka, Masahiro Aoshima
    2019 Volume 58 Issue 20 Pages 3013-3017
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Hepatitis B virus (HBV) is one of the main causes of polyarteritis nodosa (PAN). We herein report a rare case of HBV-associated vasculitis presenting with multiple pulmonary nodules, mimicking granulomatous polyangiitis (GPA), with no abnormalities of the ear, nose, or kidney. A surgical lung biopsy revealed geographic necrosis surrounded by palisading granuloma and capillaritis. Because the HBV surface antigen was positive with a serum HBV-DNA level of 2.9 log10 copies/mL, we first treated the patient with entecavir and 2 weeks of prednisone 50 mg/day. The pulmonary nodules resolved, and seroconversion was observed after one month.

    Download PDF (1303K)
  • Naoto Mochizuki, Satoshi Ano, Norihiro Kikuchi, Chio Sakai, Michiko Ma ...
    2019 Volume 58 Issue 20 Pages 3019-3023
    Published: October 15, 2019
    Released: October 15, 2019
    JOURNALS OPEN ACCESS

    A 54-year-old man started to take oren-gedoku-to (coptis detoxifying decoction) because he was experiencing chronic hot flashes, night sweats and insomnia. He developed a high fever from the day of intake. At day 17, he stopped taking oren-gedoku-to because of malaise and chills, and he was admitted to our hospital. Drug-induced pneumonitis was suspected, and all drugs were stopped. Consequently, his symptoms, laboratory data and chest X-ray findings markedly improved. The results of a lymphocyte stimulation test were positive for oren-gedoku-to and one of its components, ougon (Baikal skullcap). Based on these findings, we diagnosed him with pneumonitis caused by ougon.

    Download PDF (1074K)
  • Keima Ito, Tetsuya Oguri, Akiko Nakano, Kensuke Fukumitsu, Satoshi Fuk ...
    2019 Volume 58 Issue 20 Pages 3025-3028
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 63-year-old man had received chemoradiotherapy 7 years ago for stage IIIA pulmonary adenocarcinoma of the left lower lobe and stereotactic irradiation 3 years ago for stage IA pulmonary squamous cell carcinoma of the left upper lobe. An esophageal stent was placed because of esophageal narrowing caused by tumor invasion. Five months later, he was diagnosed with an aortoesophageal fistula. Because invasive surgery posed challenges, thoracic endovascular aortic repair (TEVAR) was performed. We report this rare case of aortoesophageal fistula treated using TEVAR. However, the therapeutic effect was temporary. Further studies investigating the indications for TEVAR are warranted.

    Download PDF (1494K)
  • Susumu Noguchi, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Tomok ...
    2019 Volume 58 Issue 20 Pages 3029-3031
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 69-year-old woman underwent left upper lobectomy for left upper lobe lung adenocarcinoma. She later perceived a left visual field defect, and a brain metastasis was detected on head magnetic resonance imaging (MRI). Epidermal growth factor receptor (EGFR) testing identified two separate EGFR mutations: an L858R mutation in exon 21 and a de novo T790M mutation in exon 20. Treatment with osimertinib was started. After one month, head MRI showed that the brain metastasis had shrunk, and the visual field defect had also improved. In this case, first-line osimertinib was effective for treating brain metastasis of de novo T790M-positive lung cancer.

    Download PDF (669K)
  • Hiromi Watanabe, Kadoaki Ohashi, Kazuya Nishii, Keisuke Seike, Go Maki ...
    2019 Volume 58 Issue 20 Pages 3033-3037
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: July 10, 2019
    JOURNALS OPEN ACCESS

    Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PD-L1)-negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for more than 2 years. A pathological examination revealed infiltration of CD8-positive lymphocytes and macrophages expressing CD68, CD206, and PD-L1 into the PD-L1-negative tumor; CD206 expression is a marker of immunosuppressive tumor-associated macrophages (TAMs). The presence of PD-L1-positive TAMs in the tumor environment might be a predictor of a positive response to anti-PD-1 antibodies.

    Download PDF (1976K)
  • Yong-mei Guo, Nagi Takahashi, Ken Miyabe, Makoto Yoshida, Fumito Abe, ...
    2019 Volume 58 Issue 20 Pages 3039-3043
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Severe hepatic failure is rarely a cause of death in patients with immunoglobulin light chain (AL) amyloidosis. We herein report a case of AL amyloidosis involving a bleeding tendency due to factor X deficiency and marked hepatic involvement of amyloidosis. The patient died due to severe liver dysfunction two weeks after admission. The diagnosis was confirmed histologically by AL-λ amyloidosis, with the liver and spleen as the main lesions, on an autopsy. As treatment-related toxicity is strong in advanced cases, appropriate treatments are required to improve the prognosis of AL amyloidosis with severe liver dysfunction.

    Download PDF (759K)
  • Yuji Yamamoto, Yasushi Otani, Fukuko Okabe, Midori Yoneda, Osamu Morim ...
    2019 Volume 58 Issue 20 Pages 3045-3050
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and diffuse eosinophilic infiltration. Although cardiovascular involvement is common and a leading cause of EGPA-related mortality, severe pericarditis-led cardiac tamponade occurs rarely. We herein report a 72-year-old man with anti-proteinase 3 (anti-PR3) anti-neutrophil cytoplasmic antibody (ANCA)-positive EGPA diagnosed by the presence of cardiac tamponade, which responded quickly to pericardiocentesis and a single administration of prednisolone. This is the first case of anti-PR3 ANCA-positive EGPA with cardiac tamponade; the patient displayed clinical features of both ANCA-positive and ANCA-negative cases.

    Download PDF (1006K)
  • Hiroshi Oiwa, Kohei Taniguchi, Natsuki Miyoshi, Keiko Sasaki, Kouichi ...
    2019 Volume 58 Issue 20 Pages 3051-3055
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    A 45-year-old man was admitted with acute abdominal pain and eosinophilia. Abdominal computed tomography revealed thickness of the ascending and transverse colon with decreased contrast enhancement and a small amount of ascites. In an emergency operation, the necrotic colon was resected. Histopathology showed subserous medium-sized arteritis with abundant eosinophil infiltrates and thrombosis in the portal vein branches. He was diagnosed with polyarteritis nodosa (PAN), and immunosuppressive therapy improved his condition. Two years later, the disease recurred with ischemic cutaneous lesions and marked eosinophilia. Our experience suggests that marked eosinophilia in PAN may imply severe organ involvement, including gastrointestinal necrosis, as well as the association of venous thrombosis.

    Download PDF (1085K)
  • Ikuto Takeuchi, Youichi Yanagawa, Hiroki Nagasawa, Kei Jitsuiki, Shuns ...
    2019 Volume 58 Issue 20 Pages 3057-3059
    Published: October 15, 2019
    Released: October 15, 2019
    [Advance publication] Released: June 27, 2019
    JOURNALS OPEN ACCESS

    An 86-year-old woman intentionally drank approximately 300 mL of a glyphosate-surfactant. She was found with consciousness disturbance and experienced several vomiting episodes. On arrival, serum biochemistry revealed a decreased level of butyrylcholinesterase (B-CHE) [11 (normal range: 180-450) IU/L]. Later, her B-CHE level further decreased to single-digit values, and she became comatose with involuntary movement and an increase in muscle tone. Her consciousness level and muscle tone improved with the recovery of her B-CHE level. Physicians should be alert for the occurrence of intermediate syndrome when the B-CHE levels of patients who have consumed a massive amount of glyphosate-surfactant show a prolonged decrease.

    Download PDF (215K)
PICTURES IN CLINICAL MEDICINE
feedback
Top